GlassScriptPhysician profile
Katrina L Kelly
NPI 1861588543
$2,044.56
in general payments reported to CMS, 2019-2025
25 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $89.81 · 2021: $353 · 2022: $278 · 2023: $325 · 2024: $339 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.70 | 2019-2023 | |
| Astellas Pharma US INC | $382.24 | 2019-2024 | Veozah |
| Mayne Pharma Commercial LLC | $272.28 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.42 | 2019-2025 | |
| Organon LLC | $94.79 | 2021-2023 | Nexplanon |
| Coopersurgical, INC. | $91.79 | 2019-2025 | Paragard T 380a |
| Allergan, INC. | $87.77 | 2019 | |
| Aspira Women'S Health INC | $74.96 | 2021-2024 | Ova1 |
| Therapeuticsmd, INC. | $61.30 | 2020-2022 | |
| Myovant Sciences INC. | $61.22 | 2021-2022 | |
| Viiv Healthcare Company | $52.04 | 2025 | Apretude |
| Sumitomo Pharma America, INC. | $48.53 | 2023 | Myfembree |
| Exeltis, USA INC. | $41.85 | 2019-2020 | |
| Duchesnay USA Incorporated | $35.03 | 2019 | |
| Merck Sharp & Dohme LLC | $32.79 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $28.94 | 2025 | Solosec, Phexx, Phexxi |
| Ethicon US, LLC | $26.88 | 2020 | |
| Daiichi Sankyo INC. | $26.10 | 2024 | Injectafer |
| Minerva Surgical, INC | $19.46 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $17.09 | 2023 | Vivjoa |
| Ascend Therapeutics US, LLC | $16.97 | 2023 | |
| Amag Pharmaceuticals, INC. | $15.17 | 2019 | |
| Pfizer INC. | $14.76 | 2023 | |
| Lupin INC. | $13.91 | 2019 | |
| Avion Pharmaceuticals | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.